¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Cancer Chemother Biol Response Modif"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • chemotactic response
    È­ÇÐÁÖ¼º¹ÝÀÀ, È­Çнò¸²¹ÝÀÀ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • evoked response
    À¯¹ß¹ÝÀÀ
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • frequency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • inverse response
    ¿ª¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • inert response
    ºÒȰ¼º¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • response curve
    ¹ÝÀÀ°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • delayed response
    Áö¿¬¹ÝÀÀ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • emotional response
    °¨Á¤¹ÝÀÀ
  • evoked response
    À¯¹ß¹ÝÀÀ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦
  • inert response
    ºÒȰ¼º¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • radiation response
    ¹æ»ç¼±¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ(ÔÑê¬Úãëë).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • lung cancer
    Æó¾Ï(øË ).
  • mammary cancer
    À¯¾Ï(À¯¾Ï).
  • mammary cancer
    À¯¾Ï(êáäß)
  • maxillary cancer
    »ó¾Ç¾Ï
  • maxillary cancer
    »ó¾Ç¾Ï(ß¾äÉäß)
  • medullary cancer
    ¼öÁú¼º¾Ï(âÐòõàõäß).
  • medullary cancer
    ¼öÁú¼º¾Ï(¡­äß)
  • medullary cancer
    ¼öÁú¼º¾Ï(Ëà̤ËÛËâ).
  • metastatic cancer
    ÀüÀ̼º ¾Ï(¡­äß).
  • metastatic cancer
    ÀüÀ̼º ¾Ï(¡­äß)
  • mucinoid cancer
    Á¡¾×¼º ¾Ï(Á¡¾×¼º¾Ï).
  • mucinoid cancer
    Á¡¾×¼º ¾Ï(ïÄäûàõäß).
  • mule spinner s cancer
    ¸é¹æÀû°ø¾Ï(ËÎËÑËø Ë­Ëâ).
  • mule spinner s cancer
    ¸é¹æÀû°ø¾Ï(ØúÛ·îà Íïäß).
  • noma =water cancer
    ¼ö¾Ï(â©äß) ±«Àú¼º ±¸³»¿°(ÎÕîÅàõ Ï¢Ò®æú)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MLR mean length response; middle latency response; mixed lymphocyte reaction
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
SER sebum excretion rate; sensitizer enhancement ratio; sensory evoked response; service; smooth endopla...
SIRS soluble immune response suppressor; Structured Interview of Reported Symptoms; systemic inflammatory...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CCG Cancer Group
CIS Cancer Information Service
CP Cancer Procoagulant
CCSG Cancer Study Group
CALGB Cancer and Leukaemia Group B
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • evoked response
    À¯¹ß ¹ÝÀÀ
  • humoral immunologic response
    ü¾×¼º ¸é¿ª ¹ÝÀÀ
  • immediate response
    Ãʱ⠹ÝÀÀ
    ¾Ë·¹¸£±â ¹ÝÀÀ°ú °°ÀÌ À¯¹ßÀÎÀÚ¿¡ Á¢ÇÑ ÈÄ, ¸î ÃÊ-¸î ºÐ À̳»¿¡ ÃâÇöÇÏ´Â ¹ÝÀÀ.
  • immune response
    ¸é¿ª ¹ÝÀÀ
  • immunologic response
    ¸é¿ª ¹ÝÀÀ
    Ç׿ø¿¡ ³ëÃâµÊÀ¸·Î½á °³Ã¼ÀÇ ¹ÝÀÀ¼ºÀÌ Æ¯ÀÌÀûÀ¸·Î º¯È­ÇÑ »óÅÂ.
  • learned response
    ÇнÀ ¹ÝÀÀ
    ÇнÀÀ» ½ÃŰ´Â ÀÚ°¡ ÀǵµÇÑ ´ë·Î Çൿ. ¿¹¸¦ µé¸é Á¾ÀÌ ¿ï·Áµµ °³°¡ ħÀ» È긮´Â °ÍÀÌ ÀÖ´Ù.
  • localized protective response
    ±¹¼ÒÀû º¸È£ ¹ÝÀÀ
  • memory immune response
    ¸é¿ªÇÐÀû ±â¾ï ¹ÝÀÀ
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • placebo response
    Çö󼼺¸ ¹ÝÀÀ, °¡¾à ¹ÝÀÀ
  • psychophysiologic response
    ½É¸® »ý¸®Àû ¹ÝÀÀ
  • response
    ¹ÝÀÀ, ÀÀ´ä
    Àڱؿ¡ ÀÇÇÏ¿© ÀϾ´Â ÀÛ¿ëÀ̳ª ¿òÁ÷ÀÓ.
  • response to illness
    Áúº´¿¡ ´ëÇÑ ¹ÝÀÀ
  • sensitization response
    °¨ÀÛ ¹ÝÀÀ
  • stimulus response assessment
    ÀÚ±Ø ¹ÝÀÀ Æò°¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
immune-response gene <molecular biology> Any of several genes of the major histocompatibility complex that control the immune response of lymphocytes to specific antigens.
(09 Oct 1997)
immune response genes Gene's in the HLA-D region of the histocompatibility complex of human chromosome 6 which control the immune response to specific antigens.
(05 Mar 2000)
inflammatory response A part of innate immunity. Inflammation occurs when tissues are injured by viruses, bacteria, trauma, chemicals, heat, cold or any other harmful stimulus. Chemicals including bradykinin, histamine, serotonin and others are released by specialised cells. These chemicals attract tissue macrophages and white blood cells to localise in an area to engulf (phagocytize) and destroy foreign substances. A byproduct of this activity is the formation of pus--a combination of white blood cells, bacteria and foreign debris. The chemical mediators released during the inflammatory response give rise to the typical findings associated with inflammation.
(27 Sep 1997)
isomorphic response An isomorphic reaction seen in response to trauma in previously uninvolved sites of patients with skin diseases including psoriasis and lichen planus, typically with lesions in a linear pattern at sites of scratching or a scar.
Synonym: isomorphic response.
(05 Mar 2000)
oculomotor response Widespread myogenic potential evoked by visual stimuli.
(05 Mar 2000)
orienting response An aspect of attending in which an organism's initial response to a change or to a novel stimulus is such that the organism becomes more sensitive to the stimulation; e.g., dilation of the pupil of the eye in response to dim light.
Synonym: investigatory reflex, orienting response.
(05 Mar 2000)
overall response rate <pharmacology> Sum of complete and partial tumour responses seen in a study, divided by the number of evaluable patients.
(05 Jan 1998)
target response In conditioning, any behaviour or specific response chosen by the experimenter; its frequency is intended to increase or decrease by the judicious pairing with it of a reinforcer when it occurs.
Synonym: target behaviour, target response.
(05 Mar 2000)
th1 response <immunology> An acquired immune response whose most prominent feature is high cytotoxic T lymphocyte activity relative to the amount of antibody production. The Th1 response is promoted by CD4+ Th1 T-helper cells.
See: Th2 Response.
(09 Oct 1997)
th2 response <immunology> An acquired immune response whose most prominent feature is high antibody production relative to the amount of cytotoxic T lymphocyte activity The Th2 response is promoted by CD4+ Th2 T-helper cells.
See: TO Response.
(09 Oct 1997)
early-phase response Prompt onset of symptoms following an antigenic stimulus.
(05 Mar 2000)
triple response <immunology> The vascular changes in the skin in response to mild mechanical injury, an outward spreading zone of reddening flare) followed rapidly by a weal (swelling) at the site of injury.
Redness, heat and swelling, three of the cardinal signs of inflammation, are present.
(18 Nov 1997)
evoked response An alteration in the electrical activity of a region of the nervous system through which an incoming sensory stimulus is passing; may be somatosensory (SER), auditory (BAER), or visual (VER).
See: evoked potential.
(05 Mar 2000)
evoked response audiometry A type of electrophysiologic audiometry in which electrical potentials of neural impulses from the cochlear nerve and various levels in the brain in response to acoustic stimulation are used to localise the site of a lesion causing a hearing loss.
(05 Mar 2000)
unconditioned response A response, such as salivation, which is a part of the animal or human repertoire.
Compare: conditioned response.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á